Nasopharyngeal carcinoma: cross-border specialty drug access for international patients

Quick orientation

Nasopharyngeal carcinoma has substantial geographic variation in incidence. Southern China, Southeast Asia, and parts of North Africa have the highest rates. Globally, approximately 130,000 new cases are diagnosed each year.

Typical age of onset. Most commonly diagnosed between ages 30 and 60.

Severity tiers. Severity depends on stage and EBV association. Early-stage disease has good prognosis; advanced disease is more challenging.

Why specialty drugs for Nasopharyngeal carcinoma are hard to access internationally

Penpulimab and toripalimab are PD-1 inhibitors with primary nasopharyngeal carcinoma labels. Toripalimab was FDA-approved in 2023 with a nasopharyngeal indication. International registration outside China and the US is in early stages.

Treatments approved by the FDA

• Loqtorzi (toripalimab-tpzi) — FDA approval: 2023. Mechanism: PD-1 monoclonal antibody for nasopharyngeal carcinoma. Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 130,000 per year. Country pricing: India · Qatar · Kuwait · Jordan.
• Penpulimab (penpulimab-kcqx) — FDA approval: 2025. Mechanism: PD-1 monoclonal antibody. Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 130,000 per year. Country pricing: Saudi Arabia · Qatar.

Cross-border pathways used for Nasopharyngeal carcinoma

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm nasopharyngeal carcinoma histology and EBV status.
• Document stage and prior therapy.
• Immune-related adverse event monitoring per checkpoint inhibitor protocol.
• Coordinate with head and neck oncology team.
• Some destination countries have specific protocols for checkpoint inhibitor importation.

Common questions

How does Loqtorzi compare to other PD-1 inhibitors?

Loqtorzi has a specific nasopharyngeal carcinoma label. Other PD-1 inhibitors are sometimes used off-label.

Is Loqtorzi available in my country?

Registration varies. We confirm by destination.

How long is treatment?

Treatment continues as long as benefit is observed and tolerability allows.

What about combination chemotherapy?

Standard first-line therapy combines PD-1 inhibition with platinum-based chemotherapy. Your oncologist sets the protocol.

What documents are required?

Oncologist's prescription, pathology report, imaging, and treatment history.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Nasopharyngeal carcinoma, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Nasopharyngeal carcinoma

Reserved for you.